New Gene Delivery Vehicle Shows Promise for Human Brain Gene Therapy

Gene therapy has the potential to revolutionize the treatment of severe genetic brain disorders that currently have limited treatment options. However, one major obstacle has been the challenge of delivering therapeutic cargos across the blood-brain barrier. In a groundbreaking study, researchers from the Broad Institute of MIT and Harvard have engineered a gene-delivery vehicle that shows promise in effectively crossing this barrier.

Overcoming the Blood-Brain Barrier Challenge

The research team focused on adeno-associated viruses (AAVs), which are commonly used as vehicles for gene therapies. While AAVs have been successful in delivering therapies to target cells, they struggle to efficiently cross the blood-brain barrier. This limitation has hindered the development of safer and more effective gene therapies for brain diseases.

Targeting the Transferrin Receptor

Led by Ben Deverman, an institute scientist at the Broad, the team engineered an AAV that targets a human protein called the transferrin receptor, which is highly expressed in the blood-brain barrier. In their study published in Science, they demonstrated that their AAV crossed into the brain at much higher levels than the FDA-approved AAV9 used in gene therapies for the central nervous system. Furthermore, their AAV successfully delivered a disease-relevant gene to a large fraction of brain cells, including neurons and astrocytes.

Potential Therapeutic Applications

The researchers believe that their AAV could be particularly effective in treating neurodevelopmental disorders, lysosomal storage diseases, and neurodegenerative diseases caused by mutations in a single gene. These include conditions such as Rett syndrome, Gaucher’s disease, Parkinson’s disease, and Huntington’s disease.

Advantages of the Engineered AAV

The development of this AAV is a significant step forward in enabling gene therapies for the central nervous system. The researchers are confident that if their AAV performs as expected in humans, it will be far more effective than current options. The potential impact on patients’ lives could be immense.

Innovative Screening Method

In contrast to the traditional approach of developing AAVs through animal testing, the research team utilized a screening method that involved testing AAVs in a test tube for their ability to bind to a specific human protein. This approach allowed them to identify an AAV that effectively crossed into human brain cells and bypassed a human cell model of the blood-brain barrier.

Scalable Manufacturing and Future Potential

The researchers also highlighted that their AAVs have similar production and purification yields as AAV9, making them ideal for scalable manufacturing methods.

While further development is needed to enhance the gene-delivery efficiency of these AAVs and address potential challenges, such as liver accumulation and inactivation by antibodies, the potential of this gene-delivery vehicle is immense. Researchers working on treatments for diseases like prion disease are excited about the possibilities that these AAVs unlock.

Looking to rent eco-friendly equipment for your next big project? Turn to Eco-Rental Solutions. To get started, request a quote.